Anti-VEGF agents for age-related macular degeneration

Bibliography

• Bressler NM, Bressler SB, Congdon NG, Age-Related Eye Disease Study Research Group: Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol 2003;121:1621-4
   PubMed Web of Science ®Google Scholar
• Friedman DS, O’Colmain BJ, Muñoz B, Eye Diseases Prevalence Research Group: Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-72
   PubMed Web of Science ®Google Scholar
• Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med 2008;358:2606-17
   PubMed Web of Science ®Google Scholar
• Chong EW, Kreis AJ, Wong TY, Dietary omega-3 fatty acid and fish intake in the primary prevention of age-related macular degeneration: a systematic review and meta-analysis. Arch Ophthalmol 2008;126:826-33
   PubMedGoogle Scholar
• Hooper P, Jutai JW, Strong G, Russell-Minda E. Age-related macular degeneration and low-vision rehabilitation: a systematic review. Can J Ophthalmol 2008;43:180-7
   PubMed Web of Science ®Google Scholar
• Klein R. Overview of progress in the epidemiology of age-related macular degeneration. Ophthalmic Epidemiol 2007;14:184-7
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Moss SE. Relation of smoking to the incidence of age-related maculopathy. The Beaver DamEye Study. Am J Epidemiol 1998;147:103-10
   PubMed Web of Science ®Google Scholar
• Radimer KL, Subar AF, Thompson FE. Nonvitamin, nonmineral dietary supplements: issues and findings from NHANES III. J Am Diet Assoc 2000;100:447-54
   PubMedGoogle Scholar
• Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. Am J Ophthalmol 2004;137:486-95
   PubMed Web of Science ®Google Scholar
• Edwards AO, Ritter R, Abel KJ, Complement factor H polymorphism and age-related macular degeneration. Science 2005;308:421-4
   PubMed Web of Science ®Google Scholar
• Haines JL, Hauser MA, Schmidt S, Complement factor H variant increases the risk of age-related macular degeneration. Science 2005;308:419-21
   PubMed Web of Science ®Google Scholar
• Hageman GS, Anderson DH, Johnson LV. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA 2005;102:7227-32
   PubMed Web of Science ®Google Scholar
• Jakobsdottir J, Conley YP, Weeks DE, Susceptibility genes for age-related maculopathy on chromosome 10q26. Am J Hum Genet 2005;77:389-407
   PubMed Web of Science ®Google Scholar
• Gold B, Merriam JE, Zernant J. Variation in factor B (BF) and complement component 2 (C2)genes is associated with age-related macular degeneration. Nat Genet 2006;38:458-62
   PubMed Web of Science ®Google Scholar
• Johnson LV, Leitner WP, Staples MK, Anderson DH. Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. Exp Eye Res 2001;73:887-96
   PubMed Web of Science ®Google Scholar
• Esparza-Gordillo J, Soria JM, Buil A, Genetic and environmental factors influencing the human factor H plasma levels. Immunogenetics 2004;56:77-82
   PubMed Web of Science ®Google Scholar
• Thornton J, Edwards R, Mitchell P, Smoking and age-related macular degeneration: a review of association. Eye 2005;19:935-44
   PubMed Web of Science ®Google Scholar
• Sangiovanni JP, Chew EY, Clemons TE, The relationship of dietary lipid intake and age-related macular degeneration in a case-control study: AREDS Report No. 20. Arch Ophthalmol 2007;125:671-9
   PubMed Web of Science ®Google Scholar
• Seddon JM, George S, Rosner B. Cigarette smoking, fish consumption, omega-3 fatty acid intake, and associations with age-related macular degeneration: the US Twin Study of Age-Related Macular Degeneration. Arch Ophthalmol 2006;124:995-1001
   PubMed Web of Science ®Google Scholar
• Clemons TE, Milton RC, Klein R, Age-related Eye Disease Study. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119:1417-36
   PubMedGoogle Scholar
• Chen J, Fitzke F, Pauleikhoff D, Bird A. Functional loss in age-related Bruch's membrane change with choroidal perfusion defect. Invest Ophthalmol Vis Sci 1992;33:334-40
   PubMed Web of Science ®Google Scholar
• Ciulla TA. Evolving pathophysiological paradigms for age related macular degeneration. Br J Ophthalmol 2001;85:510-2
   PubMed Web of Science ®Google Scholar
• Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol 2007;18:502-8
   PubMed Web of Science ®Google Scholar
• Pasqualetti G, Danesi R, Del Tacca M, Bocci G. Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy. Pharmacogenomics 2007;8:49-66
   PubMed Web of Science ®Google Scholar
• Macular Photocoagulation Study Group. Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Arch Ophthalmol 1994;112:500-9
   PubMedGoogle Scholar
• Bressler NM. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (Tap) Study Group: photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two year results of 2 randomized clinical trials–TAP report no. 2. Arch Ophthalmol 2001;119:198-207
   PubMed Web of Science ®Google Scholar
• Arnold JJ, Blinder KJ, Bressler NM, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group; Verteporfin in Photodynamic Therapy Study Group. Acute severe visual acuity decrease after photodynamic therapy with verteporfin: Case reports from randomized clinical trials–TAP and VIP report no. 3. Am J Ophthalmol 2004;137:683-96
   PubMed Web of Science ®Google Scholar
• Michels S, Schmidt-Erfurth U. Photodynamic therapy with verteporfin: a new treatment in ophthalmology. Semin Ophthalmol 2001;16:201-16
   PubMedGoogle Scholar
• Azab M, Boyer DS, Bressler NM, Visudyne in Minimally Classic Choroidal Neovascularization Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 2005;123:448-57
   PubMed Web of Science ®Google Scholar
• Bressler NM. Verteporfin in Photodynamic Therapy Study Group: Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization–verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001;131:541-60
   PubMed Web of Science ®Google Scholar
• Eter N, Vogel A, Inhetvin-Hutter C, Spitznas M. Interval reduction of photodynamic therapy (PDT) in age-related macular degeneration (AMD) is not advantageous. A pilot project. Ophthalmologe 2003;100:314-7
   PubMed Web of Science ®Google Scholar
• Treatment of Age-related Macular Degeneration with Photodynamic Therapy (Tap) Study Group: photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials–TAP Report 1. Arch Ophthalmol 1999;117:1329-45
   PubMed Web of Science ®Google Scholar
• Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005;112:301-4
   PubMed Web of Science ®Google Scholar
• Gillies MC, Simpson JM, Luo W, A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: One-year results. Arch Ophthalmol 2003;121:667-73
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Michels S, Augustin A. Perspectives on verteporfin therapy combined with intravitreal corticosteroids. Arch Ophthalmol 2006;124:561-3
   PubMedGoogle Scholar
• Ozkiris A, Erkilic K. Complications of intravitreal injection of triamcinolone acetonide. Can J Ophthalmol 2005;40:63-8
   PubMed Web of Science ®Google Scholar
• Brown MM, Brown GC, Brown H. Value-based medicine and interventions for macular degeneration. Curr Opin Ophthalmol 2007;18:194-200
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Adamis AP, Cunningham JR, VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16
   PubMed Web of Science ®Google Scholar
• Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005;69:11-6
   PubMed Web of Science ®Google Scholar
• Michels S, Rosenfeld PJ, Puliafito CA, Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005;112:1035-47
   PubMed Web of Science ®Google Scholar
• Rich RM, Rosenfeld PJ, Puliafito CA, Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511
   PubMed Web of Science ®Google Scholar
• Avery RL, Pieramici DJ, Rabena MD, Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-72
   PubMed Web of Science ®Google Scholar
• Van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. JAMA 2005;293:1509-13
   PubMed Web of Science ®Google Scholar
• LUCENTIS [package insert]: South San Francisco, CA: Genentech Inc. 2006
   Google Scholar
• Gaudreault J, Fei D, Rusit J, Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005;46:726-33
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, MARINA Study Group: ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31
   PubMed Web of Science ®Google Scholar
• Regillo CD, Brown DM, Abraham P, Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-48
   PubMed Web of Science ®Google Scholar
• Kaiser PK, Brown DM, Zhang K, Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 2007;144:850-7
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Levy DE, O’Dwyer PJ, Eastern ooperative Oncology Group. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the eastern cooperative oncology group study E2200. Ann Oncol 2006;17:1399-403
   PubMed Web of Science ®Google Scholar
• Miskala PH, Bass EB, Bressler NM, Submacular Surgery Trials (SST) Research Group. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: quality-of-life findings: SST report no. 12. Ophthalmology 2004;111:1981-92
   PubMed Web of Science ®Google Scholar
• coll GE, Sparrow JR, Marinovic A, Effect of intravitreal tissue plasminogen activator on experimental subretinal hemorrhage. Retina 1995;15:319-26
   PubMed Web of Science ®Google Scholar
• Stifter E, Michels S, Prager F, Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage. Am J Ophthalmol 2007;144:886-92
   PubMed Web of Science ®Google Scholar
• Meyer CH, Scholl HP, Eter N, Combined treatment of acute subretinal haemorrhages with intravitreal recombined tissue plasminogen activator, expansile gas and bevacizumab: a retrospective pilot study. Acta Ophthalmol 2008;86:490-4
   PubMed Web of Science ®Google Scholar
• D’Amico DJ, Goldberg MF, Hudson H, Anecortave Acetate Clinical Study Group: anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy. Retina 2003;23:14-23
   PubMed Web of Science ®Google Scholar
• Raju TN. The Nobel chronicles, 1978. Lancet 1999;354:1567
   PubMedGoogle Scholar
• Holash J, Davis S, Papadopoulos N, VEGF-Trap: A VEGF blocker with potent antitumor effects. PNAS 2002;99:11393-8
   PubMed Web of Science ®Google Scholar
• Genentech, Inc. US2008226629; 2008
   Google Scholar
• Kyowa Hakko Kogyo KK. US20060277121; 2008
   Google Scholar
• Regeneron Pharma. WO2006086544; 2007
   Google Scholar
• Csl Ltd. WO2007AU00799; 2007
   Google Scholar
• Regeneron Pharma. KR20067000521; 2006
   Google Scholar
• Astrazeneca AB. US20040566841; 2007
   Google Scholar
• Lilly Co. EP20060735794; 2008
   Google Scholar
• Bayer Schering Pharma AG. CN20058038187; 2007
   Google Scholar
• Novartis AG. AU20020351909; 2007
   Google Scholar
• Novartis AG. RU20020121645; 2007
   Google Scholar
• Childrens Medical Center. NZ535670; 2006
   Google Scholar
• Schering AG. WO2006EP02342; 2006
   Google Scholar
• Cti Europ Srl. US20050517805; 2006
   Google Scholar
• Methylgene Inc. EP20060851548; 2008
   Google Scholar